Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06791525 · ClinicalTrials.gov registry record · Phase 4
Tirbanibulin for Pediatric Warts
A Phase 4 study of Warts Hand, sponsored by The Skin Center Dermatology Group.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06791525 is a Phase 4 study of Warts Hand that is actively recruiting participants, run by The Skin Center Dermatology Group. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06791525, a Phase 4 study of Warts Hand, is actively recruiting participants, sponsored by The Skin Center Dermatology Group.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5-fluorouracil, have low efficacy and require prolonged use. Case reports suggest tirbanibulin ointment may provide an effective and well-tolerated alternative for pediatric warts. This study will evaluate the efficacy and safety of tirbanibulin ointment in treating pediatric hand warts.
Conditions Studied
Interventions
- DRUG Tirbanibulin ointment 1%
Study Locations (1)
New York
- The Skin Center Dermatology Group - New City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06791525
The ClinicalTrials.gov registry entry for NCT06791525 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Skin Center Dermatology Group, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Warts Hand appearing as the primary indexed condition, and to 1 intervention - of which Tirbanibulin ointment 1% is the first listed.
NCT06791525 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06791525 about?
NCT06791525 is a clinical study titled "Tirbanibulin for Pediatric Warts". Warts are common, benign skin lesions caused by the human papillomavirus (HPV). Treatment is challenging, particularly in the pediatric population, where standard modalities such as cryotherapy and intralesional immunotherapy are poorly tolerated. Existing topical treatments, such as imiquimod and 5...
What is the current status of trial NCT06791525?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2025-05-01. Estimated completion is 2025-12-30.
What conditions does trial NCT06791525 study?
This clinical trial studies the following conditions: Warts Hand.
What interventions are being tested in trial NCT06791525?
The interventions under investigation include: Tirbanibulin ointment 1% (DRUG).
Who is sponsoring clinical trial NCT06791525?
This trial is sponsored by The Skin Center Dermatology Group, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06791525 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.